Clinicians Medication overview

Mounjaro gains a cardiovascular risk-reduction indication

Originally posted Aug 2026 · By Joe Zucchi, PA-C, MPAS

Download PNG ↓Original LinkedIn post ↗

1227 × 1536 px · PDF includes the original image and a link to this page.

Joe’s original LinkedIn post

About this visual

The FDA expanded Mounjaro’s label for adults with type 2 diabetes at high cardiovascular risk, based on SURPASS-CVOT against dulaglutide.

❤️ Big news today for tirzepatide and cardiovascular health.

The FDA has officially expanded the indication for Mounjaro (tirzepatide), approving it to reduce the risk of major cardiovascular events, including cardiovascular death, nonfatal heart attack, and nonfatal stroke, in adults with type 2 diabetes who are at high risk for these events.

This approval was based on the SURPASS-CVOT trial, which followed more than 13,000 people with type 2 diabetes and established cardiovascular disease for about four years.

One of the more interesting parts of this study is that Mounjaro was not compared with placebo. It was compared directly with Trulicity, another GLP-1 medication that already has proven cardiovascular benefit.

In the trial, major cardiovascular events occurred in 12.1% of patients taking Mounjaro compared with 13.0% taking Trulicity.

So, Mounjaro performed at least as well as Trulicity from a cardiovascular standpoint, which was the main goal of the study. There was also an 8% lower rate of cardiovascular death, heart attack, or stroke with Mounjaro compared with Trulicity, although the study did not prove that Mounjaro was statistically superior. All-cause mortality was also 16% lower with tirzepatide.

The bigger picture here is that these medications continue to show benefits that go far beyond lowering blood sugar or helping with weight loss.

We are seeing more and more evidence that treating metabolic disease appropriately can have a real impact on cardiovascular health, sleep apnea, kidney disease, liver disease, and other obesity-related conditions.

This is another important step forward for tirzepatide and another reminder that these medications are about much more than the number on the scale.

#Mounjaro #Tirzepatide #GLP1 #Type2Diabetes #CardiovascularHealth #ObesityMedicine #CardiometabolicHealth Eli Lilly and Company

Sources & further reading

Original LinkedIn post ↗

Further reading: Current Mounjaro prescribing information ↗

Further reading: SURPASS-CVOT trial publication ↗

The trial tested noninferiority against dulaglutide in type 2 diabetes; superiority was not established. See the current FDA label for the exact indication.

Related visuals

Mounjaro gains a cardiovascular risk-reduction indication

Pinch to zoom on touch devices. Open full image ↗